Skip to content
2000
Volume 32, Issue 34
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML
Preview this article:
Preview Magnify

There is no abstract available.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673356301250130074521
2025-02-11
2025-10-31

  • From This Site

    /content/journals/cmc/10.2174/0109298673356301250130074521
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmc/32/34/CMC-32-34-06.html?itemId=/content/journals/cmc/10.2174/0109298673356301250130074521&mimeType=html&fmt=ahah

References

  1. OlsonM. LockhartT.E. LiebermanA. Motor learning deficits in Parkinson’s disease (PD) and their effect on training response in gait and balance: A narrative review.Front. Neurol.201910FEB6210.3389/fneur.2019.0006230761061
     [Google Scholar]
  2. DoroszkiewiczJ. GroblewskaM. MroczkoB. Molecular biomarkers and their implications for the early diagnosis of selected neurodegenerative diseases.Int. J. Mol. Sci.2022239461010.3390/ijms2309461035563001
     [Google Scholar]
  3. KhatriD.K. ChoudharyM. SoodA. SinghS.B. Anxiety: An ignored aspect of Parkinson’s disease lacking attention.Biomed. Pharmacother.202013111077610.1016/j.biopha.2020.11077633152935
     [Google Scholar]
  4. PrengerM.T.M. MadrayR. Van HedgerK. AnelloM. MacDonaldP.A. Social symptoms of Parkinson’s disease.Parkinsons Dis.2020202011010.1155/2020/884654433489081
     [Google Scholar]
  5. WatanabeH. DijkstraJ.M. NagatsuT. Parkinson’s Disease: Cells succumbing to lifelong dopamine-related oxidative stress and other bioenergetic challenges.Int. J. Mol. Sci.2024254200910.3390/ijms2504200938396687
     [Google Scholar]
  6. GadhaveD.G. SugandhiV.V. JhaS.K. NangareS.N. GuptaG. SinghS.K. DuaK. ChoH. HansbroP.M. PaudelK.R. Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance.Ageing Res. Rev.20249910235710.1016/j.arr.2024.10235738830548
     [Google Scholar]
  7. Radlicka-BorysewskaA. JabłońskaJ. LenarczykM. SzumiecŁ. HardaZ. BagińskaM. BarutJ. PeraJ. KreinerG. WójcikD.K. Rodriguez ParkitnaJ. Non-motor symptoms associated with progressive loss of dopaminergic neurons in a mouse model of Parkinson’s disease.Front. Neurosci.202418April137526510.3389/fnins.2024.137526538745938
     [Google Scholar]
  8. MasatoA. PlotegherN. BoassaD. BubaccoL. Impaired dopamine metabolism in Parkinson’s disease pathogenesis.Mol. Neurodegener.20191413510.1186/s13024‑019‑0332‑630630532
     [Google Scholar]
  9. BäckströmD. Eriksson DomellöfM. GranåsenG. LinderJ. MayansS. ElghE. ZetterbergH. BlennowK. ForsgrenL. Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson’s disease.Acta Neurol. Scand.20181371919810.1111/ane.1281228869277
     [Google Scholar]
  10. SalahuddinP. FatimaM.T. UverskyV.N. KhanR.H. IslamZ. FurkanM. The role of amyloids in Alzheimer’s and Parkinson’s diseases.Int. J. Biol. Macromol.2021190445510.1016/j.ijbiomac.2021.08.19734480905
     [Google Scholar]
  11. MehraS. GadheL. BeraR. SawnerA.S. MajiS.K. Structural and functional insights into α-synuclein fibril polymorphism.Biomolecules20211110141910.3390/biom1110141934680054
     [Google Scholar]
  12. FarottiL. Paolini PaolettiF. SimoniS. ParnettiL. Unraveling pathophysiological mechanisms of Parkinson’s disease: Contribution of CSF biomarkers.Biomark. Insights20201510.1177/117727192096407733110345
     [Google Scholar]
  13. MahboobA. AliH. AlnaimiA. YousefM. Al-muhannadiN.A. KalanaD. SenevirathneL. RobM. ChaariA. Immunotherapy for Parkinson’s disease and alzheimer’s disease: A promising disease-modifying therapy.Cells20241318152710.3390/cells13181527
     [Google Scholar]
  14. van OostveenW.M. de LangeE.C.M. Imaging techniques in Alzheimer’s disease: A review of applications in early diagnosis and longitudinal monitoring.Int. J. Mol. Sci.2021224211010.3390/ijms2204211033672696
     [Google Scholar]
  15. DirkxM.F. BolognaM. The pathophysiology of Parkinson’s disease tremor.J. Neurol. Sci.202243512019610.1016/j.jns.2022.12019635240491
     [Google Scholar]
  16. RameshS. ArachchigeA.S.P.M. Depletion of dopamine in Parkinson’s disease and relevant therapeutic options: A review of the literature.AIMS Neurosci.202310320023110.3934/Neuroscience.202301737841347
     [Google Scholar]
  17. PalmisanoC. BrandtG. VissaniM. PozziN.G. CanessaA. BrumbergJ. MarottaG. VolkmannJ. MazzoniA. PezzoliG. FrigoC.A. IsaiasI.U. Gait initiation in Parkinson’s disease: impact of dopamine depletion and initial stance condition.Front. Bioeng. Biotechnol.2020813710.3389/fbioe.2020.0013732039188
     [Google Scholar]
  18. PonsiG. ScattolinM. VillaR. AgliotiS.M. Human moral decision-making through the lens of Parkinson’s disease.NPJ Park. Dis.2021711810.1038/s41531‑021‑00167‑w33654110
     [Google Scholar]
  19. ArgerichJ. GarmaL.D. López-CanoM. Álvarez-MontoyaP. Gómez-AceroL. Fernández-DueñasV. Muñoz-ManchadoA.B. AsoE. BoxerA. Andres-BenitoP. GPR37 processing in neurodegeneration: A potential marker for Parkinson’s disease progression rate.NPJ Park. Dis.202410117210.1038/s41531‑024‑00788‑x39256360
     [Google Scholar]
  20. MederD. HerzD.M. RoweJ.B. LehéricyS. SiebnerH.R. The role of dopamine in the brain - lessons learned from Parkinson’s disease.Neuroimage2019190190799310.1016/j.neuroimage.2018.11.02130465864
     [Google Scholar]
  21. BraniganK.S. DottaB.T. Cognitive Decline: Current intervention strategies and integrative therapeutic approaches for Alzheimer’s disease.Brain Sci.202414429810.3390/brainsci1404029838671950
     [Google Scholar]
  22. MelesS.K. OertelW.H. LeendersK.L. Circuit imaging biomarkers in preclinical and prodromal Parkinson’s disease.Mol. Med.202127111110.1186/s10020‑021‑00327‑x34530732
     [Google Scholar]
  23. WallerS. WilliamsL. Morales-BriceñoH. FungV.S.C. The initial diagnosis and management of Parkinson’s disease.Aust. J. Gen. Pract.2021501179380010.31128/AJGP‑07‑21‑608734713282
     [Google Scholar]
  24. RizviS.Z.H. PalimarV. GuptaC. AndradeL.S. Spectrum of non-motor symptoms in Parkinson’s disease - a review.Anna. Clini. Exper. Neurol.2024183728010.17816/ACEN.1001
     [Google Scholar]
  25. FabbriM. CoelhoM. GaronM. BiundoR. MestreT.A. AntoniniA. Personalized care in late-stage Parkinson’s disease: Challenges and opportunities.J. Pers. Med.202212581310.3390/jpm1205081335629235
     [Google Scholar]
  26. WillisA.W. Parkinson disease in the elderly adult.Mo. Med.2013110540641024279192PMC6179875
     [Google Scholar]
  27. ShinH.W. HongS.W. YounY.C. Clinical aspects of the differential diagnosis of Parkinson’s disease and parkinsonism.J. Clin. Neurol.202218325927010.3988/jcn.2022.18.3.25935589315
     [Google Scholar]
  28. KoeglspergerT. RumpfS.L. SchließerP. StruebingF.L. BrendelM. LevinJ. TrenkwalderC. HöglingerG.U. HermsJ. Neuropathology of incidental Lewy body & prodromal Parkinson’s disease.Mol. Neurodegener.20231813210.1186/s13024‑023‑00622‑737173733
     [Google Scholar]
  29. Van Den BergeN. UlusoyA. Animal models of brain-first and body-first Parkinson’s disease.Neurobiol. Dis.202216310559910.1016/j.nbd.2021.10559934952161
     [Google Scholar]
  30. SurmeierD.J. Determinants of dopaminergic neuron loss in Parkinson’s disease.FEBS J.2018285193657366810.1111/febs.1460730028088
     [Google Scholar]
  31. FormisanoR. RosikonK.D. SinghA. DhillonH.S. The dopamine membrane transporter plays an active modulatory role in synaptic dopamine homeostasis.J. Neurosci. Res.202210081551155910.1002/jnr.2496534747520
     [Google Scholar]
  32. EgamiK. YittaS. KasimS. LewersJ.C. RobertsR.C. LeharM. JinnahH.A. Basal ganglia dopamine loss due to defect in purine recycling.Neurobiol. Dis.200726239640710.1016/j.nbd.2007.01.01017374562
     [Google Scholar]
  33. SalonJ.A. LodowskiD.T. PalczewskiK. The significance of G protein-coupled receptor crystallography for drug discovery.Pharmacol. Rev.201163490193710.1124/pr.110.00335021969326
     [Google Scholar]
  34. BeaulieuJ.M. EspinozaS. GainetdinovR.R. Dopamine receptors – IUPHAR review 13.Br. J. Pharmacol.2015172112310.1111/bph.1290625671228
     [Google Scholar]
  35. AsadiA. Madadi AslM. ValizadehA. PercM. Dynamics of parkinsonian oscillations mediated by transmission delays in a mean-field model of the basal ganglia.Front. Cell. Neurosci.202418134414910.3389/fncel.2024.134414938550919
     [Google Scholar]
  36. ChantranupongL. BeronC.C. ZimmerJ.A. WenM.J. WangW. SabatiniB.L. Dopamine and glutamate regulate striatal acetylcholine in decision-making.Nature2023621797957758510.1038/s41586‑023‑06492‑937557915
     [Google Scholar]
  37. CrambK.M.L. Beccano-KellyD. CraggS.J. Wade-MartinsR. Impaired dopamine release in Parkinson’s disease.Brain202314683117313210.1093/brain/awad06436864664
     [Google Scholar]
  38. KawahataI. FinkelsteinD.I. FukunagaK. Dopamine D1-D5 receptors in brain nuclei: Implications for health and disease.Receptors20243215518110.3390/receptors3020009
     [Google Scholar]
  39. NeupaneS. De CeccoE. AguzziA. The hidden cell-to-cell trail of α-synuclein aggregates.J. Mol. Biol.20234351216793010.1016/j.jmb.2022.16793036566800
     [Google Scholar]
  40. ShenW. ZhaiS. SurmeierD.J. Striatal synaptic adaptations in Parkinson’s disease.Neurobiol. Dis.202216710568610.1016/j.nbd.2022.10568635272023
     [Google Scholar]
  41. Halli-tierneyA.D. LukerJ. A comprehensive approach to Parkinson’s disease: Addressing its molecular, clinical, and therapeutic aspects.Park. Dis.202010211172838
     [Google Scholar]
  42. ÖzçeteÖ.D. BanerjeeA. KaeserP.S. Mechanisms of neuromodulatory volume transmission.Mol. Psychiatry202429113680369310.1038/s41380‑024‑02608‑338789677
     [Google Scholar]
  43. FreedW.J. Motive Desire A New W. to Think About Why We Do Everything Its Basis Neuroscience.ChamSpringer International Publishing202210.1007/978‑3‑031‑10477‑0
     [Google Scholar]
  44. HauserR.A. LeWittP.A. ComellaC.L. HauserR.A. LewittP.A. ComellaC.L. On demand therapy for Parkinson’s disease patients: Opportunities and choices.Postgrad. Med.2021133772172710.1080/00325481.2021.193608734082655
     [Google Scholar]
  45. HaddadF. SawalhaM. KhawajaY. NajjarA. KaramanR. Dopamine and levodopa prodrugs for the treatment of Parkinson’s disease.Molecules20172314010.3390/molecules2301004029295587
     [Google Scholar]
  46. CarrollV. RossiterR. BlanchardD. Non-motor symptoms of Parkinson’s disease.Aust. J. Gen. Pract.2021501181281710.31128/AJGP‑07‑21‑609334713279
     [Google Scholar]
  47. Dong-ChenX. YongC. YangX. Chen-YuS. Li-HuaP. Signaling pathways in Parkinson’s disease: Molecular mechanisms and therapeutic interventions.Signal Transduct. Target. Ther.2023817310.1038/s41392‑023‑01353‑336810524
     [Google Scholar]
  48. YamashitaK.Y. BhoopatirajuS. SilverglateB.D. GrossbergG.T. Biomarkers in Parkinson’s disease: A state of the art review.Biomark. Neuropsychiatry2023910007410.1016/j.bionps.2023.100074
     [Google Scholar]
  49. JostS.T. KaldenbachM.A. AntoniniA. Martinez-MartinP. TimmermannL. OdinP. KatzenschlagerR. BorgohainR. FasanoA. StocchiF. HattoriN. KukkleP.L. Rodríguez-ViolanteM. Falup-PecurariuC. SchadeS. Petry-SchmelzerJ.N. MettaV. WeintraubD. DeuschlG. EspayA.J. TanE.K. BhidayasiriR. FungV.S.C. CardosoF. TrenkwalderC. JennerP. Ray ChaudhuriK. DafsariH.S. Levodopa Dose Equivalency in Parkinson’s Disease: Updated systematic review and proposals.Mov. Disord.20233871236125210.1002/mds.2941037147135
     [Google Scholar]
  50. AdamH. GopinathS. C. B. Md ArshadM. K. AdamT. ParminN. A. HuseinI. HashimU. An update on pathogenesis and clinical scenario for Parkinson's disease: Diagnosis and treatment.3 Biotech202313514210.1007/s13205‑023‑03553‑8
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673356301250130074521
Loading
Impaired Striatum Dopamine Release in Parkinson’s Disease
Curr. Med. Chem. 32, 7554 (2025); https://doi.org/10.2174/0109298673356301250130074521
/content/journals/cmc/10.2174/0109298673356301250130074521
/content/journals/cmc/10.2174/0109298673356301250130074521
Loading

Data & Media loading...


  • Article Type:     Editorial

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test